Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 11/2017

01.11.2017 | Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)

Post-Infectious Irritable Bowel Syndrome

verfasst von: Yeong Yeh Lee, Chandramouli Annamalai, Satish S. C. Rao

Erschienen in: Current Gastroenterology Reports | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Post-infectious irritable bowel syndrome (PI-IBS) is characterized by persistent abdominal pain and diarrhea, typically following an episode of infectious gastroenteritis. The mechanisms that underlie IBS-D remain elusive, but PI-IBS provides a mechanistic model of this disorder. This review provides an up-to-date appraisal of the pathophysiology, clinical features, and management approaches for PI-IBS.

Recent Findings

Disordered immune reactions and release of cytokines with resultant gut inflammation and dysfunction appear to be key features of PI-IBS. Disordered brain-gut-microbiota interactions, type of infecting agent, and host-genetic susceptibility are risk factors but also are reasons for the varying spectrum of clinical severity. Although prognosis is generally good, symptoms and inflammation may persist for a long time. Symptomatic relief with antidiarrheals, antispasmodics, 5HT3 antagonists, mesalamine, probiotics, and low-dose antidepressants remain the primary approaches, but in some difficult cases, a combination of drugs that target the pathophysiology may be helpful.

Summary

PI-IBS has many overlapping features with IBS-D and shares similar pathophysiology and management approaches.
Literatur
1.
2.
Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of post-infective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578–83.CrossRefPubMed
3.
Chaudhary NA, Truelove SC. The irritable colon syndrome: a study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med. 1962;31:307–22.PubMed
4.
•• Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins S. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445–50. This is considered to many as the landmark study of post-infectious IBS. CrossRefPubMed
5.
Borgaonkar MR, Ford DC, Marshall JK, Churchill E, Collins SM. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci. 2006;51:1026–32.CrossRefPubMed
6.
Ilnyckyj A, Balachandra B, Elliott L, Choudhri S, Duerksen DR. Post-traveler’s diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol. 2003;98:596–9.CrossRefPubMed
7.
Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in north American travelers to Mexico. Am J Gastroenterol. 2004;99:1774–8.CrossRefPubMed
8.
9.
McKendrick M, Read N. Irritable bowel syndrome—post salmonella infection. J Inf Secur. 1994;29:1–3.
10.
Mearin F, Badia X, Balboa A, Baró E, Caldwell E, Cucala M, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol. 2001;36:1155–61.CrossRefPubMed
11.
Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler’s diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006;43:898–0.CrossRefPubMed
12.
Kim HS, Kim MS, Ji SW, Park H. The development of irritable bowel syndrome after Shigella infection: 3 year follow-up study. Korean J Gastroenterol. 2006;47:300–5.PubMed
13.
Moss-Morris R, Spence M. To “lump” or to “split” the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome? Psychosom Med. 2006;68:463–9.CrossRefPubMed
14.
Spence MJ, Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut. 2007;56:1066–71.CrossRefPubMedPubMedCentral
15.
16.
Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome—a meta-analysis. Am J Gastroenterol. 2006;101:1894–9.CrossRefPubMed
17.
Thabane M, Kottachchi D, Marshall J. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535–44.CrossRefPubMed
18.
Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Collins SM, et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010;105:933–9.CrossRefPubMed
19.
Mutsch M, Pitzurra R, Hatz C, Steffen R. Post-infectious Sequelae of Travelers' diarrhea: irritable bowel syndrome. J Travel Med. 2014;21:141–3.CrossRefPubMed
20.
Lee YY, Rao SC. Post-infectious irritable bowel syndrome. Biota-Scope 2015;2:10–6.
21.
•• Lawenko RMA, Lee YY, Nurfadhilah Y, Yaacob N, Mohammad WMZW, Liong MT, et al. The role of gut dysbiosis and probiotics in persistent abdominal pain following a major flood disaster. J Gastroenterol Hepatol. 2016;31:131. This study provides evidence for IBS akin to post-infectious IBS following a major disaster and that probiotic is useful in such a situation.
22.
Neal K, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314:779–82.CrossRefPubMedPubMedCentral
23.
Ibarra C, Herrera V. Pérez dAE, Gil L, Madrid A, Valenzuela L, et al. Parasitosis and irritable bowel syndrome. Rev Chil Infectol. 2016;33:268–74.CrossRef
24.
Motomura Y, Khan WI, El-Sharkawy RT, Verma-Gandhu M, Grencis RK, Collins SM. Mechanisms underlying gut dysfunction in a murine model of chronic parasitic infection. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1354–60.CrossRefPubMed
25.
Beatty J, Bhargava A, Buret A. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol. 2014;20:3976–85.CrossRefPubMedPubMedCentral
26.
Teoh DA, Kamieniecki D, Pang G, Buret AG. Giardia Lamblia rearranges F-actin and α-actinin in human colonic and duodenal monolayers and reduces transepithelial electrical resistance. J Parasitol. 2000;86:800–6.PubMed
27.
Hanevik K, Dizdar V, Langeland N, Hausken T. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol. 2009;9:1–5.CrossRef
28.
Buret AG. Pathophysiology of enteric infections with Giardia duodenalis. Parasite. 2008;15:261–5.CrossRefPubMed
29.
Long Y, Wang W, Wang H, Hao L, Qian W, Hou X. Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome. J Gastroenterol Hepatol. 2012;27:935–44.CrossRefPubMed
30.
Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2:119–29.CrossRefPubMed
31.
•• Ghoshal UC, Gwee K-A. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link. Nat Rev Gastroenterol Hepatol. 2017;14:435–41. This review provides some thought provoking issues in relation to tropical sprue and how it is associated with post-infectious IBS CrossRefPubMed
32.
Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373–82.CrossRefPubMed
33.
Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.CrossRefPubMedPubMedCentral
34.
•• Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et al. Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63:1737–45. The faecal microbiota of patients with PI-IBS differ from that of healthy controls and resemble patients with IBS-D, suggesting a common pathophysiology. CrossRefPubMed
35.
Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121:799–804.CrossRefPubMed
36.
37.
Van Der Veek PP, Van Den Berg M, De Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol. 2005;100:2510–6.CrossRefPubMed
38.
Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–13.CrossRefPubMed
39.
Spiller RC, Jenkins D, Thornley JM, Hebden J, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acuteCampylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–11.CrossRefPubMedPubMedCentral
40.
Keating C, Beyak M, Foley S, Singh G, Marsden C, Spiller R, et al. Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol. 2008;586:4517–30.CrossRefPubMedPubMedCentral
41.
Barbara G, Wang B, Stanghellini V, De Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.CrossRefPubMed
42.
Mearin F, Perelló A, Balboa A, Perona M, Sans M, Salas A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol. 2009;44:1173–85.CrossRefPubMed
43.
Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.CrossRefPubMed
44.
Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71–8.CrossRefPubMed
45.
Sundin J, Rangel I, Kumawat AK, Hultgren-Hörnquist E, Brummer RJ. Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. Scand J Gastroenterol. 2014;49:1068–75.CrossRefPubMed
46.
Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist E, Vos W, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 2015;41:342–51.CrossRefPubMed
47.
Gwee K, Collins S, Read N, Rajnakova A, Deng Y, Graham J, et al. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523–6.CrossRefPubMedPubMedCentral
48.
Ghoshal UC, Shukla R, Ghoshal U, Gwee K-A, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:13.CrossRef
49.
Lee YA, Nam YH, Min A, et al. Entamoeba histolytica-secreted cysteine proteases induce IL-8 production in human mast cells via a PAR2-independent mechanism. Parasite. 2014;21:1.CrossRefPubMedPubMedCentral
50.
Clarke G, McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Increased Kynurenine production following toll-like receptor (TLR) activation: a novel role for Tlr8 in irritable bowel syndrome (IBS). Gastroenterology. 2011;140(5):S-111.
51.
Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011;106(2):329–36.CrossRefPubMed
52.
Belmonte L, Youmba SB, Bertiaux-Vandaele N, Antonietti M, Lecleire S, Zalar A, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One. 2012;7:e42777.CrossRefPubMedPubMedCentral
53.
Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol. 2012;15:57–62.CrossRefPubMed
54.
Faure M, Moënnoz D, Montigon F, Mettraux C, Breuillé D, Ballèvre O. Dietary threonine restriction specifically reduces intestinal mucin synthesis in rats. J Nutr. 2005;135:486–91.PubMed
55.
Kashyap PC, Marcobal A, Ursell LK, Smits SA, Sonnenburg ED, Costello EK, et al. Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiota. Proc Natl Acad Sci U S A. 2013;110:17059–64.CrossRefPubMedPubMedCentral
56.
Simpson J, Sundler F, Humes D, Jenkins D, Wakelin D, Scholefield J, et al. Prolonged elevation of galanin and tachykinin expression in mucosal and myenteric enteric nerves in trinitrobenzene sulphonic acid colitis. Neurogastroenterol Motil. 2008;20:392–406.CrossRefPubMed
57.
Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923–9.CrossRefPubMedPubMedCentral
58.
Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123:1972–9.CrossRefPubMed
59.
Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol. 2009;24:1601–7.CrossRefPubMed
60.
Wouters MM, Van Wanrooy S, Nguyen A, Dooley J, Aguilera-Lizarraga J, Van Brabant W, et al. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut. 2016;65:1279–88.CrossRefPubMed
61.
Kiank C, Taché Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun. 2010;24:41–8.CrossRefPubMed
62.
Clarke G, Cryan J, Dinan T, Quigley EM. Probiotics for the treatment of irritable bowel syndrome–focus on lactic acid bacteria. Aliment Pharmacol Ther. 2012;35:403–13.CrossRefPubMed
63.
Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002;47:2625–34.CrossRefPubMed
64.
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–51.CrossRefPubMed
65.
Cuomo R, Savarese MF, Gargano R. Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues. Dig Dis. 2007;25:241–4.CrossRefPubMed
66.
Verdu EF, Bercik P, Verma-Gandhu M, Huang X-X, Blennerhassett P, Jackson W, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182–90.CrossRefPubMedPubMedCentral
67.
Parry SD, Barton JR, Welfare MR. Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur J Gastroenterol Hepatol. 2005;17:1071–5.CrossRefPubMed
68.
Lee YY, Waid A, Tan HJ, Chua AS, Whitehead WE. Rome III survey of irritable bowel syndrome among ethnic Malays. World J Gastroenterol. 2012;18:6475–80.CrossRefPubMedPubMedCentral
69.
McCarroll MG, Riddle MS, Gutierrez RL, Porter CK. Infectious gastroenteritis as a risk factor for tropical Sprue and Malabsorption: a case–control study. Dig Dis Sci. 2015;60:3379–85.CrossRefPubMed
70.
David L-E, Surdea-Blaga T, Dumitrascu D-L. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study. Sao Paulo Med J. 2015;133:343–9.CrossRefPubMed
71.
Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015;10:e0126438.CrossRefPubMedPubMedCentral
72.
•• Marshall J, Thabane M, Garg A, Clark W, Moayyedi P, Collins S. Walkerton health study investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605–11. This study provides data on prognosis of post-infectious IBS for eight years. CrossRefPubMed
73.
• Abdul Rani R, Ali R, Affendi R, Lee YY. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res. 2016;14:297–304. Both IBD and IBS have significant overlap in terms of symptoms, pathophysiology, and treatment, suggesting the possibility of IBS and IBD being a single disease entity albeit at opposite ends of the spectrum. CrossRefPubMedPubMedCentral
74.
Hilmi I, Hartono JL, Pailoor J, Mahadeva S, Goh K-L. Low prevalence of ‘classical’microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea. BMC Gastroenterol. 2013;13:80.CrossRefPubMedPubMedCentral
75.
Porter CK, Cash BD, Pimentel M, Akinseye A, Riddle MS. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 2012;12:55.CrossRefPubMedPubMedCentral
76.
Efskind P, Bernklev T, Vatn M. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996;31(5):463–8.CrossRefPubMed
77.
Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19–31. Epub 2003/07/10 CrossRefPubMed
78.
Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro R, De Giorgio R, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009;30:245–52.CrossRefPubMed
79.
Andrews C, Griffiths T, Kaufman J, Vergnolle N, Surette M, Rioux K. Mesalazine (5- aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea- predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(3):374–83.CrossRefPubMed
80.
Lam C, Tan W, Leighton M, Hastings M, Lingaya M, Falcone Y, et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhea (IBS-D). Gut. 2016;65:91–9.CrossRefPubMed
81.
Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481–9.CrossRefPubMed
82.
Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. I. A C. Am J Gastroenterol. 2006; 101:326.
83.
•• Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32. In this landmark trial, rifaximin has been shown to be effective in IBS-D and possibility post-infectious IBS too. CrossRefPubMed
84.
Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with Rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151:1113–21.CrossRefPubMed
85.
Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 Mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007;102:1709.CrossRefPubMed
86.
Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12:953–9.CrossRefPubMed
87.
Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150:358–66.e8.CrossRefPubMed
88.
Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, et al. A randomised atrial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617–25.CrossRefPubMed
89.
• Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0172846. Ramosetron, cilansetron, ondansetron, and alosetron are effective for treating non-constipated IBS and IBS-D. This systematic review found only rare serious adverse events associated with these drugs. CrossRefPubMedPubMedCentral
90.
Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, et al. Cytokine and clinical response to saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol. 2014;26:630–9.CrossRefPubMed
91.
Symons P, Jones M, Kellow J. Symptom provocation in irritable bowel syndrome effects of differing doses of fructose-sorbitol. Scand J Gastroenterol. 1992;27:940–4.CrossRefPubMed
92.
Goldstein R, Braverman D, Stankiewicz H. Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints. Isr Med Assoc J. 2000;2:583–7.PubMed
93.
Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. 2012;5:261–8.CrossRefPubMedPubMedCentral
94.
Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016;55:897–906.CrossRefPubMed
95.
Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Syst Rev. 2011;8:CD003460.
96.
Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–12.PubMed
97.
Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145:329–38.CrossRefPubMed
98.
Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–26.CrossRefPubMed
Metadaten
Titel
Post-Infectious Irritable Bowel Syndrome
verfasst von
Yeong Yeh Lee
Chandramouli Annamalai
Satish S. C. Rao
Publikationsdatum
01.11.2017
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 11/2017
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-017-0595-4

Weitere Artikel der Ausgabe 11/2017

Current Gastroenterology Reports 11/2017 Zur Ausgabe

GI Oncology (R Bresalier, Section Editor)

Endoscopic and Imaging Predictors of Complete Pathologic Response After Chemoradiation for Esophageal Cancer

Nutrition and Obesity (S McClave and J Obert, Section Editors)

Going Gluten Free: the History and Nutritional Implications of Today’s Most Popular Diet

Liver (E Kallwitz and S Cotler, Section Editors)

Liver Masses: What Physicians Need to Know About Ordering and Interpreting Liver Imaging

Nutrition and Obesity (S McClave and J Obert, Section Editors)

Phenotypes of Obesity: How it Impacts Management

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise